Novartis (NYSE:NVS) announced Friday that the European Medicines Agency (EMA), endorsed Fabhalta for the treatment of adults ...

C3 AI (NYSE: AI), the Enterprise AI application software company, today announced that C3 AI Chairman and CEO Thomas M.

A new study highlights the importance of normal serology in reducing severe and renal flares in systemic lupus erythematosus ...

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase ...

Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacopl ...

C3.ai, Inc. (AI) stock plunged nearly 10% on Thursday despite the enterprise artificial intelligence software applications ...

Apple's new 'e' series smartphone could be a regular thing: new iPhone 16e would be followed up by iPhone 17e in 2026 with in ...

Shares of C3.ai ( AI -6.27%) are falling on Thursday. The company's stock had lost 6.4% as of 2:10 p.m. ET, but was down as ...

Carlos Sainz set the pace for Williams ahead of Ferrari pair Lewis Hamilton and Charles Leclerc, as rain impacted the second ...

Specifically, the C3.ai founder and CEO left C3 Agentic AI to tackle the broad business highlights and trends out of the firm ...

JP Morgan analyst maintains Underweight rating on C3.ai with $27 price target, citing subpar growth, small scale, and ...